Introducing
Your new presentation assistant.
Refine, enhance, and tailor your content, source relevant images, and edit visuals quicker than ever before.
Trending searches
68Ga Advancements....
[68Ga-DOTA,Tyr3]octreotide (DOTA-TOC)
[68Ga-DOTA,1-Nal]octreotide (DOTA-NOC)*
[68Ga-DOTA]-TATE*
[68Ga-DOTA]-Lanreotide
[68Ga-DOTA]-Bombesin / AMBA* and DEMOBESIN*
[68Ga-DOTA]-D-Glu-Gastrin (MTC, NET)*
[68Ga-DOTA]-F(ab’)2-herceptin (breast cancer)
68Ga-Citrate (infection, inflammation)
68Ga-DOTA-Tyrosin (brain tumors)*
68Ga-DOTA-HSA Microspheres (lung perfusion)*
68Ga-NODAGA-RGD (angiogenesis)*
68Ga-BPAMP (osteoblastic metastases)*
68Ga-DOTA-MSH (melanoma)*
68Ga-DOTA-SHAL (lymphoma)*
68Ga-PSMA (prostate cancer)
68Ga-CXCR4 (acdenocarcinomas)
* first performed at Bad Berka
World Map of Ga68 (10/1/13)
bit.ly/ga68map
You are going where ?
June 2011
400+ Medical Professionals
5 patients
Invited to join the SNMMI and subsequently the GA68 working group
A Word document later - Go2BadBerka.info
Tom O'Dorisio
Right Care, Right Patient, and Right Time
Eric Liu
Michael Schultz
Ajit Padhy
All substance are poisons, there are none which is not a poison. The right dose differentiates a poison and a remedy. Paracelsus ca. 1493-1541
PRRTInfo.org - March 2011 Launch
1,500 unique visitors every month
News and practical information on what PRRT is and how to travel for treatment
Funded and run by patients for patients
Top Articles (all viewed 1,000+ times)
Top Search Items
(over 15,000 site searches)
Lesson learned...
So much more than a 15 minute talk can do justice
20 phone calls
Six face to face meetings
Numerous drafting sessions - a pathway towards approval
48 page power point - 20 page imaging manual - 1 poster
October 2008 - Conference on NETs
PET/CT in NeuroEndocrine Tumours Session
A better imaging method for NETs
Ga-68 DOTATOC positive in only 1/22 patients presenting with symptoms / labs suggestive of elevated serotonin without diagnosis of NET (false positive)
Ga-68 DOTATOC identified primary tumor in 14/20 pts with metastatic disease, 7 have gone to surgery to remove primary. 2 others confirmed by biopsy. Conventional imaging found 3.
DOTATATE
US/Canada: Expires in 2015
Europe: Expires in 2014
DOTATOC
US/Canada: Expires in 2014
Europe: Expires in 2015
DOTANOC
US: Expires in 2022 (BioSynthema)
Everywhere else: expired
Patient Perspective on Molecular Imaging and Therapy.
Josh Mailman
President, NorCal CarciNET
Chair, Patient Advocacy and Advisory Board SNMMI
Member, GA68 Working Group
and a bunch of other stuff...
Disclosures - None
Objectives
Once Dx - there are options - but what path to choose ?
and how do you talk to people who have been there before...
Clinical efficacy analysis: Change of patient’s management 80 patients (2011-13)
No impact: 48% of patients
Inter-modality change: 42% (33/80)
Candidates for surgery: 15% (12/80), 2/3 UP
Not candidates for surgery: 4% (3/80), 1/9 diagnosis
Candidates for PRRT: 20% (16/80)
Not candidates for PRRT: 3% (2/80)
Intra-modality change: 10% (8/80)
Change in surgical plans: 3.5% (3/80)
Additional PRRT: 3.5% (3/80)
Refer to endoscopic ultrasound: 3% (2/80)
Conclusions: change in patient’s management
Restaging NET: 57% (40/70)
Diagnosis: 11% (1/9)
Selected Papers can be found at http://prrtinfo.org/index.php/news/113-pre-second-world-ga68-congress-publication
Complete abstracts: www.wjnm.org/showBackIssue.asp?issn=1450-1147;year=2013;volume=12;issue=3;month=February;supp=Y
Videos of the conference: http://itr8.com/hosted/chandighar/presentation_links.htm
Patient Perspective on Molecular Imaging and Therapy